Was Kevin Puylaert’s SOPH share sale a discretionary trade?

No, the sale was not discretionary. The footnote states the 33 shares were sold in the open market to satisfy tax obligations on restricted stock unit vesting, executed as a “sell to cover” transaction rather than an elective buy-or-sell decision.

SOPHiA GENETICS CSO sells shares for taxes

SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert reported a small tax-related share sale.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert reported a small tax-related share sale. He sold 33 ordinary shares in an open-market transaction at $4.5424 per share to satisfy tax obligations from restricted stock units vesting on May 18, 2026. Following this sell-to-cover transaction, he directly holds 148,164 ordinary shares.

Insider Trade Summary

Net Seller: 33 shares

Net Sell 1 txn

Insider Puylaert Kevin

Role Chief Sales Officer

Sold 33 shs ($149.90)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	33	$4.5424	$149.90

Holdings After Transaction: Ordinary Shares — 148,164 shares (Direct)

Footnotes (1)

F1. Represents shares sold by the Reporting Person in the open market to satisfy tax obligations in connection with the vesting of restricted stock units on May 18, 2026. The sales were effected as a "sell to cover" transaction and do not represent discretionary trades.

Key Figures

Shares sold: 33 shares Sale price: $4.5424 per share Shares held after sale: 148,164 shares

3 metrics

Shares sold 33 shares Open-market sale on May 19, 2026 to cover taxes

Sale price $4.5424 per share Average price for the 33 ordinary shares sold

Shares held after sale 148,164 shares Direct ownership following the sell-to-cover transaction

Key Terms

sell to cover, restricted stock units, open market

3 terms

sell to cover financial

"The sales were effected as a "sell to cover" transaction and do not represent discretionary trades."

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

restricted stock units financial

"to satisfy tax obligations in connection with the vesting of restricted stock units on May 18, 2026."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

open market financial

"Represents shares sold by the Reporting Person in the open market to satisfy tax obligations"

An open market is a system where buying and selling of goods, services, or financial assets happen freely without restrictions or special controls. For investors, it means they can trade assets easily and quickly, which helps determine fair prices based on supply and demand. This environment encourages transparency and competition, making it easier to buy or sell with confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did SOPH Chief Sales Officer Kevin Puylaert report?

Kevin Puylaert reported selling 33 SOPHiA GENETICS SA ordinary shares. The transaction was an open-market sale used to cover tax obligations arising from restricted stock unit vesting, rather than a discretionary portfolio decision or large position change.

At what price were the SOPH shares sold in Kevin Puylaert’s Form 4 filing?

The 33 ordinary shares were sold at an average price of $4.5424 per share. This price reflects an open-market transaction executed specifically as part of a sell-to-cover arrangement tied to recently vested restricted stock units.

How many SOPHiA GENETICS (SOPH) shares does Kevin Puylaert hold after this sale?

After the transaction, Kevin Puylaert directly holds 148,164 ordinary shares of SOPHiA GENETICS SA. The reported sale covered only 33 shares, leaving his overall share position essentially unchanged in size relative to his total holdings.

What is a sell-to-cover transaction as used in the SOPH Form 4?

A sell-to-cover transaction involves selling a portion of vested shares to pay related taxes. In this case, 33 SOPHiA GENETICS ordinary shares were sold specifically to satisfy tax obligations tied to restricted stock units that vested on May 18, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/20/2026 - 04:02 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Puylaert Kevin

(Last)

(First)

(Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE

1180

(City)

(State)

(Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Sales Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	05/19/2026		S		33⁽¹⁾	D	$4.5424	148,164	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares sold by the Reporting Person in the open market to satisfy tax obligations in connection with the vesting of restricted stock units on May 18, 2026. The sales were effected as a "sell to cover" transaction and do not represent discretionary trades.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-fact for Kevin Puylaert	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR